Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease

Biomedicine and Pharmacotherapy

Volumn 64, Issue 4, 2010, Pages 282-286

  Vamos, Eniko ^a   Voros, Krisztina ^a   Vecsei, Laszlo ^a   Klivenyi, Peter ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Antioxidant; Huntington's disease; L carnitine

Indexed keywords

CARNITINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; HUNTINGTON CHOREA; MOTOR PERFORMANCE; NEUROPROTECTION; NONHUMAN; OPEN FIELD BEHAVIOR; OXIDATIVE STRESS; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TRANSGENIC MOUSE;

ANIMALS; BEHAVIOR, ANIMAL; CARNITINE; DISEASE MODELS, ANIMAL; HUNTINGTON DISEASE; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; SURVIVAL;

EID: 77952322688     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2009.06.020     Document Type: Article

References (31)

1. Ferrante R.J., Gutekunst C.A., Persichetti F., McNeil S.M., Kowall N.W., Gusella J.F., et al. Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. J Neurosci. 1997, 17:3052-3063.
2. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
3. Gutekunst C.A., Li S.H., Yi H., Mulroy J.S., Kuemmerle S., Jones R., et al. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci. 1999, 19:2522-2534.
4. Schilling G., Becher M.W., Sharp A.H., Jinnah H.A., Duan K., Kotzuk J.A., et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet. 1999, 8:397-407.
5. Klivenyi P., Bende Z., Hartai Z., Penke Z., Nemeth H., Toldi J., et al. Behaviour changes in a transgenic model of Huntington's disease. Behav Brain Res. 2006, 169:137-141.
6. Chen Q., Surmeier D.J., Reiner A. NMDA and non-NMDA receptor-mediated excitotoxicity are potentiated in cultured striatal neurons by prior chronic depolarization. Exp Neurol. 1999, 159:283-296.
7. Antonini A., Leenders K.L., Spiegel R., Meier D., Vontobel P., Weigell-Weber M., et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 1996, 119(Pt 6):2085-2095.
8. Martin L.J., Blackstone C.D., Huganir R.L., Price D.L. Cellular localization of a metabotropic glutamate receptor in rat brain. Neuron 1992, 9:259-270.
9. Perluigi M., Poon H.F., Maragos W., Pierce W.M., Klein J.B., Calabrese V., et al. Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: a model of Huntington disease. Mol Cell Proteomics. 2005, 4:1849-1861.
10. Tabrizi S.J., Cleeter M.W., Xuereb J., Taanman J.W., Cooper J.M., Schapira A.H. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann Neurol. 1999, 45:25-32.
11. Schilling G., Coonfield M.L., Ross C.A., Borchelt D.R. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci Lett. 2001, 315:149-153.
12. Bahl J.J., Bressler R. The pharmacology of carnitine. Annu Rev Pharmacol Toxicol. 1987, 27:257-277.
13. Koudelova J., Mourek J., Drahota Z., Rauchova H. Protective effect of carnitine on lipoperoxide formation in rat brain. Physiol Res. 1994, 43:387-389.
14. Poon H.F., Farr S.A., Thongboonkerd V., Lynn B.C., Banks W.A., Morley J.E., et al. Proteomic analysis of specific brain proteins in aged SAMP8 mice treated with alpha-lipoic acid: implications for aging and age-related neurodegenerative disorders. Neurochem. Int. 2005, 46:159-168.
15. Rockia Rani P.J., Panneerselvam C. Carnitine as a free radical scavenger in aging. Exp Gerontol. 2001, 36:1713-1726.
16. Fritz I.B., rrigoni-Martelli E. Sites of action of carnitine and its derivatives on the cardiovascular system: interactions with membranes. Trends Pharmacol Sci. 1993, 14:355-360.
17. Goety C.G., Tanner C.M., Cohen J.A., Thelen J.A., Carroll V.S., Klawans H.L., et al. L-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia. Mov Disord. 1990, 5:263-265.
18. Dedeoglu A., Kubilus J.K., Jeitner T.M., Matson S.A., Bogdanov M., Kowall N.W., et al. Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci. 2002, 22:8942-8950.
19. Ferrante R.J., Andreassen O.A., Dedeoglu A., Ferrante K.L., Jenkins B.G., Hersch S.M., et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci. 2002, 22:1592-1599.
20. Klivenyi P., Ferrante R.J., Gardian G., Browne S., Chabrier P.E., Beal M.F. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. J Neurochem. 2003, 86:267-272.
21. Gardian G., Vecsei L. Huntington's disease: pathomechanism and therapeutic perspectives. J Neural Transm. 2004, 111:1485-1494.
22. McBride J.L., Ramaswamy S., Gasmi M., Bartus R.T., Herzog C.D., Brandon E.P., et al. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A 2006, 103:9345-9350.
23. Landwehrmeyer G.B., McNeil S.M., Dure L.S., Ge P., Aizawa H., Huang Q., et al. Huntington's disease gene: regional and cellular expression in brain of normal and affected individuals. Ann Neurol. 1995, 37:218-230.
24. Sharp A.H., Loev S.J., Schilling G., Li S.H., Li X.J., Bao J., et al. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron 1995, 14:1065-1074.
25. Strong T.V., Tagle D.A., Valdes J.M., Elmer L.W., Boehm K., Swaroop M., et al. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nat Genet. 1993, 5:259-265.
26. Cha J.H. Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 2000, 23:387-392.
27. Sugars K.L., Rubinsztein D.C. Transcriptional abnormalities in Huntington disease. Trends Genet. 2003, 19:233-238.
28. Beal M.F., Ferrante R.J. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat Rev Neurosci. 2004, 5:373-384.
29. Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 2001, 18:685-716.
30. Beal M.F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 1995, 38:357-366.
31. Wyttenbach A., Sauvageot O., Carmichael J., az-Latoud C., Arrigo A.P., Rubinsztein D.C. Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum. Mol. Genet. 2002, 11:1137-1151.